Cargando…
Subgroup‐specific dose finding for phase I‐II trials using Bayesian clustering
In most models and algorithms for dose‐finding clinical trials, it is assumed that the trial participants are homogeneous—the optimal dose is the same for all those who qualify for the trial. However, if there are heterogeneous populations who may benefit from the same treatment, it is inefficient t...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324955/ https://www.ncbi.nlm.nih.gov/pubmed/35429178 http://dx.doi.org/10.1002/sim.9410 |